Gyros Protein Technologies introduces PurePep EasyClean Auto Kit for Automated Parallel Peptide Purification

New automated kit overcomes major bottleneck in peptide production, providing optimized simultaneous workflows

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents, and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of its PurePep® EasyClean (PEC) Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.

Based on Gyros Protein Technologies’ orthogonal PurePep EasyClean technology, the PEC Auto Kit utilizes a simple catch-and-release methodology for purification of chemically synthesized peptides. The new Auto Kit allows users of the PurePep Chorus and Symphony® X synthesizer to perform peptide synthesis and purification on a single instrument, further increasing process efficiency.

Conventional chromatography, including reversed-phase liquid chromatography (RP-HPLC) is a major bottleneck in peptide production, both in academia and industry, due to its limited capacity in higher throughput purifications, and the significant volumes of toxic solvents required. In addition, operation of RP-HPLC is labour intensive and requires specialist skills. Gyros Protein Technologies’ PEC Auto Kit requires up to 90% less hands-on time per peptide (6 minutes vs ~ 1 hour) and 90% less solvent consumption, facilitating parallel purification of 6 or more purified peptides in under 6 hours.

Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The PEC Auto Kit is the first automated solution for parallel peptide purification to remove a major bottleneck in the downstream production process, saving time and resources for this otherwise rate-limiting and labour-intensive step. The first newly developed product in the PurePep family following acquisition of the PEC technology in 2022, the introduction of the PEC Auto Kit further reflects our commitment to providing reliable and efficient solutions for the purification of high-quality peptides for research and production.”

Adrian Glas, CEO, Peptides Speciality Laboratories, said: “As a customer, the PurePep EasyClean technology has been an established method for purification in our labs from the very beginning.The introduction of the PEC Auto kit is the missing piece to a fully automated peptide manufacturing process. Now allowing for parallel post-synthesis purification, the new platform was easily integrated into our laboratory methods and has provided immediate benefits. The automation has taken it to the next level in terms of time efficiency and resource reduction!”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version